Maha to face shortage of Remdesivir for next 2 to 3 days: Minister

Maharashtra will face a shortage of 12,000 to 15,000 Remdesivir injections: state Food and Drug Administration (FDA) minister

remdesivir, coronavirus, drugs, covid, pharma
Press Trust of India Mumbai
2 min read Last Updated : Apr 16 2021 | 6:45 PM IST

Maharashtra will face a shortage of 12,000 to 15,000 Remdesivir injections, used to treat COVID-19 patients, for the next two to three days, state Food and Drug Administration (FDA) Minister Rajendra Shingane said on Friday.

He said pharma companies manufacturing Remdesivir have stepped up production but it will take time for the new stock to reach the market.

Speaking to reporters here, he said, Companies that produce Remdesivir injection have increased their production but it will take some time for the vials to hit the market. If we consider a 10-12 per cent shortage, Maharashtra will continue to face a shortage of 12,000 to 15,000 Remdesivir vials for the next two to three days.

Blaming companies for delay in supply of the much sough-after COVID-19 drug, the FDA minister said, The heads of Remdesivir-making companies had 15 days back assured me to supply around 55,000 vials of the injection. However, till April 15 these companies could provide only 37,000 to 39,000 vials to the state.

I held a video conference meeting with the CEOs and MDs of some of the companies that produce Remdesivir today again. These companies have now assured me that supply will be streamlined April 19 onwards, he said.

He lauded the Centre's move to ban the export of Remdesivir.

"Ready stocks of Remdesivir (which were bound for shipments abroad) are available even in Maharashtra. Some of the company representatives met me with a proposal of allowing these stocks to be sold in Maharashtra, Shingane said.

"Maharashtra chief minster Uddhav Thackeray has also issued orders allowing export-bound stocks to be sold in the state (following the ban). I do not know how much such vials are available (with companies)," he said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Apr 16 2021 | 6:38 PM IST

Next Story